{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:19Z","timestamp":1790767819125,"version":"4.1.0"},"reference-count":230,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.phrs.2024.107083","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T19:51:27Z","timestamp":1706817087000},"page":"107083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?"],"prefix":"10.1016","volume":"201","author":[{"given":"Lucia","family":"La Sala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Belen","family":"Macas-Granizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Afzalpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Martin-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"D\u2019Anzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto F.E.","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Naselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio E.","family":"Pontiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cappato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/hrt.13.3.273","article-title":"The liver in heart failure relation of anatomical, functional, and circulatory changes","volume":"13","author":"Sherlock","year":"1951","journal-title":"Br. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig. Liver Dis."},{"issue":"18","key":"10.1016\/j.phrs.2024.107083_bib3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin. Sci. (Lond. )"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107083_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2024.107083_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0040-1713006","article-title":"Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future","volume":"40","author":"Adams","year":"2020","journal-title":"Semin Liver Dis."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000518407","article-title":"The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease","volume":"14","author":"Nati","year":"2022","journal-title":"J. Innate Immun."},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","article-title":"Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2024.107083_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/9780470987438.ch6","article-title":"Nash is A Genetically Determined Disease","author":"Day","year":"2004","journal-title":": Fat. Liver Dis."},{"key":"10.1016\/j.phrs.2024.107083_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.119.315856","article-title":"Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease","volume":"126","author":"Huang","year":"2020","journal-title":"Circ. Res"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bib\/6.1.23","article-title":"Bioinformatics analysis of alternative splicing","volume":"6","author":"Lee","year":"2005","journal-title":"Brief. Bioinform"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib15","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1039\/D0CS01261K","article-title":"Targeting RNA with small molecules: from fundamental principles towards the clinic","volume":"50","author":"Falese","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00284-002-3945-9","article-title":"Neomycin and paromomycin inhibit 30S ribosomal subunit assembly in Staphylococcus aureus","volume":"47","author":"Mehta","year":"2003","journal-title":"Curr. Microbiol"},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib18","first-page":"10","article-title":"retinitis drug approved","volume":"11","author":"New","year":"1998","journal-title":"Body Posit."},{"issue":"3-4","key":"10.1016\/j.phrs.2024.107083_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.phrs.2024.107083_bib21","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/genes10020092","article-title":"RNA Modifications Modulate Activation of Innate Toll-Like Receptors","volume":"10","author":"Freund","year":"2019","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10557-020-07051-4","article-title":"Modified mRNA as a Therapeutic Tool for the Heart","volume":"34","author":"Kaur","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"issue":"15","key":"10.1016\/j.phrs.2024.107083_bib26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.119.043067","article-title":"Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration","volume":"141","author":"Magadum","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2024.107083_bib27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.omtm.2020.03.019","article-title":"Optimization of 5' Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury","volume":"17","author":"Sultana","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/psp4.12301","article-title":"Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1","volume":"7","author":"Apgar","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2007.12.009","article-title":"Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice","volume":"127","author":"Creusot","year":"2008","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib30","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/mt.2010.146","article-title":"A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice","volume":"18","author":"Creusot","year":"2010","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41587-021-01024-0","article-title":"Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors","volume":"40","author":"Abramson","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd3459","article-title":"Targeting RNA to treat neuromuscular disease","volume":"10","author":"Muntoni","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9791","key":"10.1016\/j.phrs.2024.107083_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0140-6736(11)61028-3","article-title":"Exon-skipping therapy for Duchenne muscular dystrophy","volume":"378","author":"Nakamura","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","author":"Corey","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res Dev."},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrd4359","article-title":"Therapeutic targeting of microRNAs: current status and future challenges","volume":"13","author":"Li","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5848","key":"10.1016\/j.phrs.2024.107083_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1147535","article-title":"Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430","volume":"318","author":"Choi","year":"2007","journal-title":"Science"},{"issue":"5962","key":"10.1016\/j.phrs.2024.107083_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"issue":"5740","key":"10.1016\/j.phrs.2024.107083_bib39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00425-013-2019-5","article-title":"RNA interference: concept to reality in crop improvement","volume":"239","author":"Saurabh","year":"2014","journal-title":"Planta"},{"issue":"5571","key":"10.1016\/j.phrs.2024.107083_bib41","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1126\/science.1069132","article-title":"RNA-dependent RNA polymerases, viruses, and RNA silencing","volume":"296","author":"Ahlquist","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.phrs.2024.107083_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113848","article-title":"Mature miRNAs form secondary structure, which suggests their function beyond RISC","volume":"9","author":"Belter","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107083_bib43","first-page":"210","article-title":"Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model","volume":"9","author":"Reich","year":"2003","journal-title":"Mol. Vis."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.gt.3302641","article-title":"Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1","volume":"13","author":"Shen","year":"2006","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jcp.21566","article-title":"Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF","volume":"218","author":"Jiang","year":"2009","journal-title":"J. Cell Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00210-022-02287-3","article-title":"Nanomedicine and drug delivery to the retina: current status and implications for gene therapy","volume":"395","author":"Tawfik","year":"2022","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"21","key":"10.1016\/j.phrs.2024.107083_bib47","doi-asserted-by":"crossref","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","article-title":"Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat","volume":"260","author":"Soprano","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107083_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.phrs.2024.107083_bib49","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.phrs.2024.107083_bib50","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107083_bib53","first-page":"13","article-title":"Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis","volume":"2018","author":"Taubel","year":"2018","journal-title":"XVIth Int. Symp. . Amyloidosis (ISA) Kumamoto: Poster"},{"issue":"24","key":"10.1016\/j.phrs.2024.107083_bib54","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMe2010986","article-title":"Givosiran - Running RNA Interference to Fight Porphyria Attacks","volume":"382","author":"Gonzalez-Aseguinolaza","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/nat.2020.0919","article-title":"Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs","volume":"31","author":"Agarwal","year":"2021","journal-title":"Nucleic Acid. Ther."},{"issue":"9718","key":"10.1016\/j.phrs.2024.107083_bib56","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"issue":"49","key":"10.1016\/j.phrs.2024.107083_bib57","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107083_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40291-019-00438-6","article-title":"Leading RNA interference therapeutics part 2: silencing delta-aminolevulinic acid synthase 1, with a focus on givosiran","volume":"24","author":"de Paula Brand\u00e3o","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.phrs.2024.107083_bib59","unstructured":"Chong S., Agarwal S., Agarwal S., Aluri K.C., Arciprete M., Brown C., Charisse K., Cichocki J., Fitzgerald K., Goel V.: The nonclinical disposition and PK\/PD properties of GalNAc-conjugated siRNA are highly predictable and build confidence in translation to man. Drug Metabolism and Disposition, 2021."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s44161-022-00085-x","article-title":"Chasing LDL cholesterol to the bottom\u2014PCSK9 in perspective","volume":"1","author":"Libby","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"15","key":"10.1016\/j.phrs.2024.107083_bib62","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020276","article-title":"miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis","volume":"9","author":"Condrat","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.phrs.2024.107083_bib66","doi-asserted-by":"crossref","first-page":"R762","DOI":"10.1016\/j.cub.2014.06.043","article-title":"Aberrant regulation and function of microRNAs in cancer","volume":"24","author":"Adams","year":"2014","journal-title":"Curr. Biol."},{"issue":"D1","key":"10.1016\/j.phrs.2024.107083_bib67","doi-asserted-by":"crossref","first-page":"D155","DOI":"10.1093\/nar\/gky1141","article-title":"miRBase: from microRNA sequences to function","volume":"47","author":"Kozomara","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.phrs.2024.107083_bib68","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1093\/emboj\/cdf476","article-title":"MicroRNA maturation: stepwise processing and subcellular localization","volume":"21","author":"Lee","year":"2002","journal-title":"EMBO J."},{"issue":"5824","key":"10.1016\/j.phrs.2024.107083_bib69","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1139253","article-title":"Requirement of bic\/microRNA-155 for normal immune function","volume":"316","author":"Rodriguez","year":"2007","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib70","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.molcel.2004.12.002","article-title":"Transcription and processing of human microRNA precursors","volume":"16","author":"Cullen","year":"2004","journal-title":"Mol. Cell"},{"issue":"6956","key":"10.1016\/j.phrs.2024.107083_bib71","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Lee","year":"2003","journal-title":"Nature"},{"issue":"7014","key":"10.1016\/j.phrs.2024.107083_bib72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature03120","article-title":"The Microprocessor complex mediates the genesis of microRNAs","volume":"432","author":"Gregory","year":"2004","journal-title":"Nature"},{"issue":"5654","key":"10.1016\/j.phrs.2024.107083_bib73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.1090599","article-title":"Nuclear export of microRNA precursors","volume":"303","author":"Lund","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1261\/rna.5167604","article-title":"Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs","volume":"10","author":"Bohnsack","year":"2004","journal-title":"RNA"},{"issue":"6818","key":"10.1016\/j.phrs.2024.107083_bib75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.phrs.2024.107083_bib76","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1101\/gad.927801","article-title":"Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans","volume":"15","author":"Ketting","year":"2001","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.phrs.2024.107083_bib77","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.tibs.2010.03.009","article-title":"Making RISC","volume":"35","author":"Kawamata","year":"2010","journal-title":"Trends Biochem Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib78","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1073\/pnas.0710869105","article-title":"In vitro reconstitution of the human RISC-loading complex","volume":"105","author":"MacRae","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.phrs.2024.107083_bib79","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1101\/gad.1384005","article-title":"A human, ATP-independent, RISC assembly machine fueled by pre-miRNA","volume":"19","author":"Maniataki","year":"2005","journal-title":"Genes Dev."},{"issue":"5543","key":"10.1016\/j.phrs.2024.107083_bib80","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1065062","article-title":"An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans","volume":"294","author":"Lau","year":"2001","journal-title":"Science"},{"issue":"6808","key":"10.1016\/j.phrs.2024.107083_bib81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35040556","article-title":"Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA","volume":"408","author":"Pasquinelli","year":"2000","journal-title":"Nature"},{"issue":"5543","key":"10.1016\/j.phrs.2024.107083_bib82","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.1064921","article-title":"Identification of novel genes coding for small expressed RNAs","volume":"294","author":"Lagos-Quintana","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2010.03.009","article-title":"Identification of homologous microRNAs in 56 animal genomes","volume":"96","author":"Li","year":"2010","journal-title":"Genomics"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/dna.2006.0545","article-title":"Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny","volume":"26","author":"Lee","year":"2007","journal-title":"DNA Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib86","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib88","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib89","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.coi.2011.02.001","article-title":"MicroRNA control of lymphocyte differentiation and function","volume":"23","author":"Belver","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib90","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Mol. Med"},{"issue":"11","key":"10.1016\/j.phrs.2024.107083_bib91","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrd3864","article-title":"MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles","volume":"11","author":"van Rooij","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.phrs.2024.107083_bib92","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3748\/wjg.15.1665","article-title":"MicroRNA signatures in liver diseases","volume":"15","author":"Chen","year":"2009","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib93","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cvr\/cvn156","article-title":"Role of microRNAs in vascular diseases, inflammation, and angiogenesis","volume":"79","author":"Urbich","year":"2008","journal-title":"Cardiovasc Res"},{"issue":"3-4","key":"10.1016\/j.phrs.2024.107083_bib94","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaut.2009.02.012","article-title":"MicroRNA in autoimmunity and autoimmune diseases","volume":"32","author":"Pauley","year":"2009","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib95","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1750-3639.2007.00120.x","article-title":"MicroRNAs (miRNAs) in neurodegenerative diseases","volume":"18","author":"Nelson","year":"2008","journal-title":"Brain Pathol."},{"issue":"R1","key":"10.1016\/j.phrs.2024.107083_bib96","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1093\/hmg\/ddp072","article-title":"Small regulatory RNAs in neurodevelopmental disorders","volume":"18","author":"Chang","year":"2009","journal-title":"Hum. Mol. Genet"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020477","article-title":"Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity","volume":"21","author":"Garavelli","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib98","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/db20-0199","article-title":"CD31(+) Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications.","volume":"70","author":"Prattichizzo","year":"2021","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib99","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0748-2","article-title":"Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability","volume":"17","author":"La Sala","year":"2018","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-019-0824-2","article-title":"Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naive T2D","volume":"18","author":"La Sala","year":"2019","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib101","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00125-020-05237-x","article-title":"Plasma circulating miR-23\u201327\u223c24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes","volume":"63","author":"Garavelli","year":"2020","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib102","first-page":"95","article-title":"Importance of microRNAs in skin morphogenesis and diseases","volume":"17","author":"Bostjancic","year":"2008","journal-title":"Acta Derm. Alp. Pannonica Adriat."},{"issue":"43","key":"10.1016\/j.phrs.2024.107083_bib103","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1073\/pnas.0708115104","article-title":"Distinctive patterns of microRNA expression in primary muscular disorders","volume":"104","author":"Eisenberg","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010143","article-title":"Does microRNA Perturbation Control the Mechanisms Linking Obesity and Diabetes? Implications for Cardiovascular Risk","volume":"22","author":"La Sala","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/nu14102122","article-title":"Epigenetic Profiling in the Saliva of Obese Pregnant Women","volume":"14","author":"Mando","year":"2022","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib106","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-160835","article-title":"MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease","volume":"55","author":"Lusardi","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib107","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib108","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1172\/JCI59327","article-title":"MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death.","volume":"122","author":"Aurora","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"30","key":"10.1016\/j.phrs.2024.107083_bib109","doi-asserted-by":"crossref","first-page":"11151","DOI":"10.1073\/pnas.1401724111","article-title":"Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers","volume":"111","author":"Akat","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tig.2008.01.007","article-title":"MicroRNAs flex their muscles","volume":"24","author":"van Rooij","year":"2008","journal-title":"Trends Genet"},{"issue":"7","key":"10.1016\/j.phrs.2024.107083_bib111","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/aps.2018.30","article-title":"miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges","volume":"39","author":"Zhou","year":"2018","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2024.107083_bib112","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fgene.2015.00232","article-title":"miRNA therapeutics in cardiovascular diseases: promises and problems","volume":"6","author":"Nouraee","year":"2015","journal-title":"Front Genet"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib113","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nm1582","article-title":"MicroRNA-133 controls cardiac hypertrophy","volume":"13","author":"Care","year":"2007","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib114","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/HYPERTENSIONAHA.109.139519","article-title":"Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy","volume":"55","author":"Dong","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2024.107083_bib115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuroscience.2014.06.062","article-title":"Downregulation of miRNA-134 protects neural cells against ischemic injury in N2A cells and mouse brain with ischemic stroke by targeting HSPA12B","volume":"277","author":"Chi","year":"2014","journal-title":"Neuroscience"},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib116","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/jnr.23255","article-title":"Downregulation of miR-181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl-terminal hydrolase isozyme L1","volume":"91","author":"Peng","year":"2013","journal-title":"J. Neurosci. Res"},{"issue":"11","key":"10.1016\/j.phrs.2024.107083_bib117","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/jnr.23637","article-title":"Micro-RNA-30a regulates ischemia-induced cell death by targeting heat shock protein HSPA5 in primary cultured cortical neurons and mouse brain after stroke","volume":"93","author":"Wang","year":"2015","journal-title":"J. Neurosci. Res"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib118","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib119","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds","volume":"26","author":"Gallant-Behm","year":"2018","journal-title":"Wound Repair Regen."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/ars.2014.6027","article-title":"Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice","volume":"22","author":"Yang","year":"2015","journal-title":"Antioxid. Redox Signal"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbrc.2009.09.098","article-title":"microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma","volume":"390","author":"Karbiener","year":"2009","journal-title":"Biochem Biophys. Res Commun."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib122","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jb\/mvx017","article-title":"Regulation of TGF-beta-mediated endothelial-mesenchymal transition by microRNA-27.","volume":"161","author":"Suzuki","year":"2017","journal-title":"J. Biochem"},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib123","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCRESAHA.111.255737","article-title":"MicroRNA-29 in aortic dilation: implications for aneurysm formation","volume":"109","author":"Boon","year":"2011","journal-title":"Circ. Res"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib124","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.27443","article-title":"MicroRNA-29, a key regulator of collagen expression in systemic sclerosis","volume":"62","author":"Maurer","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"35","key":"10.1016\/j.phrs.2024.107083_bib125","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1073\/pnas.0805038105","article-title":"Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis","volume":"105","author":"van Rooij","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib126","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.2010121308","article-title":"TGF-beta\/Smad3 signaling promotes renal fibrosis by inhibiting miR-29","volume":"22","author":"Qin","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib127","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1681\/ASN.2011010055","article-title":"Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis","volume":"23","author":"Wang","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.23922","article-title":"Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis","volume":"53","author":"Roderburg","year":"2011","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.phrs.2024.107083_bib129","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib130","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12013-013-9672-y","article-title":"Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1","volume":"67","author":"Yildirim","year":"2013","journal-title":"Cell Biochem Biophys."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib131","doi-asserted-by":"crossref","DOI":"10.1063\/1.5087122","article-title":"Challenges and opportunities in exosome research\u2014Perspectives from biology, engineering, and cancer therapy","volume":"3","author":"Li","year":"2019","journal-title":"APL Bioeng."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib132","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1566523219666191108103739","article-title":"Effect of tumor suppressor miR-34a loaded on ZSM-5 nanozeolite in hepatocellular carcinoma: In vitro and in vivo approach","volume":"19","author":"Salah","year":"2019","journal-title":"Curr. Gene Ther."},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib133","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib134","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2014.5","article-title":"Multifunctional aptamer-miRNA conjugates for targeted cancer therapy","volume":"22","author":"Esposito","year":"2014","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib135","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib136","first-page":"1537","article-title":"Aptamer-based targeted delivery of miRNA let-7d to gastric cancer cells as a novel anti-tumor therapeutic agent","volume":"17","author":"Daei","year":"2018","journal-title":"Iran. J. Pharm. Res.: IJPR"},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib137","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib138","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat. Med"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib139","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/ijms9060978","article-title":"MicroRNA: An emerging therapeutic target and intervention tool","volume":"9","author":"Liu","year":"2008","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.786","article-title":"Silencing of microRNA families by seed-targeting tiny LNAs","volume":"43","author":"Obad","year":"2011","journal-title":"Nat. Genet"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib141","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"issue":"7","key":"10.1016\/j.phrs.2024.107083_bib142","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of microRNA therapeutics is coming of age","volume":"6","author":"van Rooij","year":"2014","journal-title":"EMBO Mol. Med"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib143","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0021-9258(19)76994-4","article-title":"The role of sialic acid in determining the survival of glycoproteins in the circulation","volume":"246","author":"Morell","year":"1971","journal-title":"J. Biol. Chem."},{"issue":"7353","key":"10.1016\/j.phrs.2024.107083_bib144","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nature10112","article-title":"MicroRNAs 103 and 107 regulate insulin sensitivity","volume":"474","author":"Trajkovski","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.phrs.2024.107083_bib145","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2024.107083_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2024.107083_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104996","article-title":"Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes","volume":"159","author":"Berra","year":"2020","journal-title":"Pharm. Res"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib148","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00592-018-1124-0","article-title":"Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting","volume":"55","author":"Simioni","year":"2018","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2024.107083_bib149","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.phrs.2018.09.003","article-title":"Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort","volume":"137","author":"Mirani","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107083_bib150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2019.06.048","article-title":"Aspirin targets P4HA2 through inhibiting NF-kappaB and LMCD1-AS1\/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.","volume":"45","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"issue":"6706","key":"10.1016\/j.phrs.2024.107083_bib151","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.phrs.2024.107083_bib152","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1073\/pnas.0605298103","article-title":"NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.","volume":"103","author":"Taganov","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023837","article-title":"Regulation of miR-146a by RelA\/NFkB and p53 in STHdh(Q111)\/Hdh(Q111) cells, a cell model of Huntington's disease","volume":"6","author":"Ghose","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14728220903431069","article-title":"The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.","volume":"14","author":"Lin","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052782","article-title":"Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha","volume":"7","author":"Feng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107083_bib156","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/ijms21218178","article-title":"Prevention of Diabetes and Cardiovascular Disease in Obesity","volume":"21","author":"La Sala","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib157","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/diabetes.52.3.846","article-title":"The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy","volume":"52","author":"Hodgkinson","year":"2003","journal-title":"Diabetes"},{"issue":"2_suppl","key":"10.1016\/j.phrs.2024.107083_bib158","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2047487319878373","article-title":"The link between diabetes and atherosclerosis","volume":"26","author":"La Sala","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2024.107083_bib159","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-016-0390-9","article-title":"Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells","volume":"15","author":"La Sala","year":"2016","journal-title":"Cardiovasc Diabetol."},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib160","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00592-018-1149-4","article-title":"Novel insights into the regulation of miRNA transcriptional control: implications for T2D and related complications","volume":"55","author":"La Sala","year":"2018","journal-title":"Acta Diabetol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib161","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01465-0","article-title":"Lower miR-21\/ROS\/HNE levels associate with lower glycemia after habit-intervention: DIAPASON study 1-year later","volume":"21","author":"La Sala","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib162","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/stem.235","article-title":"MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue","volume":"27","author":"Kim","year":"2009","journal-title":"Stem Cells"},{"issue":"11","key":"10.1016\/j.phrs.2024.107083_bib163","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/oby.20852","article-title":"Long-term inhibition of miR-21 leads to reduction of obesity in db\/db mice","volume":"22","author":"Seeger","year":"2014","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.phrs.2024.107083_bib164","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-11-7","article-title":"Gene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity","volume":"11","author":"Keller","year":"2011","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.phrs.2024.107083_bib165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.fsi.2022.02.025","article-title":"microRNA-122 regulates NF-kappaB signaling pathway by targeting IkappaBalpha in miiuy croaker, Miichthys miiuy.","volume":"122","author":"Yang","year":"2022","journal-title":"Fish. Shellfish Immunol."},{"issue":"43","key":"10.1016\/j.phrs.2024.107083_bib166","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1093\/eurheartj\/ehw146","article-title":"Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?","volume":"37","author":"Willeit","year":"2016","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib167","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1172\/JCI63966","article-title":"miR-122 regulates hepatic lipid metabolism and tumor suppression","volume":"122","author":"Wen","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib168","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1172\/JCI44883","article-title":"The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice","volume":"121","author":"Castoldi","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib169","first-page":"1130","article-title":"Diabetic Cardiomiopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study. JACC Cardiovasc Imaging","volume":"14","author":"Pofi","year":"2021"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2337\/db16-0731","article-title":"Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes","volume":"66","author":"Willeit","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2024.107083_bib171","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","article-title":"Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver","volume":"424","author":"Yamada","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib172","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023937","article-title":"Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease","volume":"6","author":"Cermelli","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107083_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2024.107083_bib175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cca.2015.05.002","article-title":"Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease","volume":"446","author":"Yamada","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib176","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13813455.2019.1640744","article-title":"The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model","volume":"127","author":"Hu","year":"2021","journal-title":"Arch. Physiol. Biochem"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib177","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.yexcr.2018.04.027","article-title":"Up-regulation of miR-122 protects against neuronal cell death in ischemic stroke through the heat shock protein 70-dependent NF-kappaB pathway by targeting FOXO3.","volume":"369","author":"Guo","year":"2018","journal-title":"Exp. Cell Res"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib178","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2016.01.039","article-title":"Role of microRNA 21 in diabetes and associated\/related diseases","volume":"582","author":"Sekar","year":"2016","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib179","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00125-017-4237-z","article-title":"MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells","volume":"60","author":"Sims","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2024.107083_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119071","article-title":"miR-125b promotes the NF-kappaB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3.","volume":"270","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib181","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jhep.2018.08.026","article-title":"MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-kappaB-TNFalpha pathway","volume":"70","author":"Zhang","year":"2019","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib182","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-021-00819-w","article-title":"The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis","volume":"43","author":"Ru","year":"2022","journal-title":"Acta Pharm. Sin."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib183","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/labinvest.2016.112","article-title":"Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice","volume":"96","author":"Kennedy","year":"2016","journal-title":"Lab Invest"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib184","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41418-017-0019-x","article-title":"miRNA-21 ablation protects against liver injury and necroptosis in cholestasis","volume":"25","author":"Afonso","year":"2018","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib185","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/hep.22838","article-title":"MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3","volume":"49","author":"Selaru","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib186","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.246","article-title":"miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice","volume":"8","author":"Rodrigues","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2024.107083_bib187","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gene.2017.06.024","article-title":"MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1","volume":"627","author":"Luo","year":"2017","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib188","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/1753425920928449","article-title":"Inhibition of microRNA-128-3p alleviates liver ischaemia-reperfusion injury in mice through repressing the Rnd3\/NF-kappaB axis","volume":"26","author":"Mou","year":"2020","journal-title":"Innate Immun."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib189","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcmgh.2015.07.007","article-title":"Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-gamma","volume":"1","author":"Povero","year":"2015","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib190","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib191","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2337\/dc16-1354","article-title":"Extracellular RNAs Are Associated With Insulin Resistance and Metabolic Phenotypes","volume":"40","author":"Shah","year":"2017","journal-title":"Diabetes Care"},{"issue":"48","key":"10.1016\/j.phrs.2024.107083_bib192","doi-asserted-by":"crossref","first-page":"12158","DOI":"10.1073\/pnas.1808855115","article-title":"Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice","volume":"115","author":"Castano","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174218","article-title":"Effect of miR-146 targeted HDMCP up-regulation in the pathogenesis of nonalcoholic steatohepatitis","volume":"12","author":"Jin","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2024.107083_bib194","first-page":"543","article-title":"miR\u2011146a improves hepatic lipid and glucose metabolism by targeting MED1","volume":"45","author":"Li","year":"2020","journal-title":"Int J. Mol. Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib195","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-020-01334-8","article-title":"Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"20","author":"Xin","year":"2020","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib196","article-title":"Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib197","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2024.107083_bib198","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.604314","article-title":"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib199","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1159\/000470822","article-title":"MicroRNA-9 Inhibits NLRP3 Inflammasome Activation in Human Atherosclerosis Inflammation Cell Models through the JAK1\/STAT Signaling Pathway","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Physiol. Biochem"},{"key":"10.1016\/j.phrs.2024.107083_bib200","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3389\/fimmu.2018.01377","article-title":"Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment","volume":"9","author":"Tahamtan","year":"2018","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib201","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3171\/2017.5.JNS163165","article-title":"Upregulation of miR-216a exerts neuroprotective effects against ischemic injury through negatively regulating JAK2\/STAT3-involved apoptosis and inflammatory pathways","volume":"130","author":"Tian","year":"2018","journal-title":"J. Neurosurg."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib202","first-page":"5374","article-title":"Relationship between the MAPK\/ERK pathway and neurocyte apoptosis after cerebral infarction in rats","volume":"23","author":"Wang","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.phrs.2024.107083_bib203","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-015-0278-0","article-title":"Short-term high glucose exposure impairs insulin signaling in endothelial cells","volume":"14","author":"De Nigris","year":"2015","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib204","article-title":"The Function of the MEF2 Family of Transcription Factors in Cardiac Development, Cardiogenomics, and Direct Reprogramming","volume":"3","author":"Desjardins","year":"2016","journal-title":"J. Cardiovasc Dev. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib205","first-page":"616","article-title":"[Study of the 482G\/A variation in PGC-1alpha gene domain MEF2C as possible mechanism of type 2 diabetes]","volume":"25","author":"Lu","year":"2008","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.phrs.2024.107083_bib206","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1053\/j.gastro.2004.07.007","article-title":"Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2","volume":"127","author":"Wang","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib207","first-page":"735","article-title":"MicroRNA\u201122 alleviates inflammation in ischemic stroke via p38 MAPK pathways","volume":"20","author":"Dong","year":"2019","journal-title":"Mol. Med Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib208","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12031-018-1067-5","article-title":"microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway","volume":"65","author":"Yao","year":"2018","journal-title":"J. Mol. Neurosci."},{"issue":"23","key":"10.1016\/j.phrs.2024.107083_bib209","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and\/or Ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.phrs.2024.107083_bib211","doi-asserted-by":"crossref","DOI":"10.1097\/FJC.0000000000001419","article-title":"Effect of Different Types and Dosages of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-Analysis","author":"Yu","year":"2023","journal-title":"J. Cardiovasc Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2024.107083_bib212","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"15","key":"10.1016\/j.phrs.2024.107083_bib213","doi-asserted-by":"crossref","first-page":"7753","DOI":"10.1093\/nar\/gkz638","article-title":"Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer","volume":"47","author":"Lai","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2024.107083_bib214","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1476-4598-10-55","article-title":"miR-34a and miR-15a\/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner","volume":"10","author":"Bandi","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2024.107083_bib215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.omtn.2019.04.003","article-title":"Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin","volume":"16","author":"Orellana","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.phrs.2024.107083_bib216","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/genes9070329","article-title":"Above the epitranscriptome: RNA modifications and stem cell identity","volume":"9","author":"Morena","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.phrs.2024.107083_bib217","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.11.011","article-title":"RNA therapy: Are we using the right molecules?","volume":"196","author":"Yu","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2024.107083_bib218","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"issue":"Supplement_1","key":"10.1016\/j.phrs.2024.107083_bib219","doi-asserted-by":"crossref","first-page":"S014","DOI":"10.1093\/ecco-jcc\/jjy222.020","article-title":"OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients","volume":"13","author":"Vermeire","year":"2019","journal-title":"J. Crohn'S. Colitis"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/genedge.4.1.10","article-title":"Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis: French biopharma gears up for Phase III trial of lead candidate ABX464 as BMS, Pfizer and Lilly pursue UC treatments","volume":"4","author":"Philippidis","year":"2022","journal-title":"GEN Edge"},{"issue":"8","key":"10.1016\/j.phrs.2024.107083_bib221","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/annrheumdis-2022-222228","article-title":"Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and\/or anti-TNFalpha therapy: a placebo-controlled phase II study","volume":"81","author":"Daien","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib222","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2006478118","article-title":"Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis","volume":"118","author":"Price","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5985","key":"10.1016\/j.phrs.2024.107083_bib223","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1126\/science.1189862","article-title":"MiR-33 contributes to the regulation of cholesterol homeostasis","volume":"328","author":"Rayner","year":"2010","journal-title":"science"},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib224","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1530\/JME-20-0324","article-title":"miR-23a\/b-3p promotes hepatic lipid accumulation by regulating Srebp-1c and Fas","volume":"68","author":"Li","year":"2022","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib225","article-title":"Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration","volume":"9","author":"Huang","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2024.107083_bib226","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2024.107083_bib227","article-title":"miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2024.107083_bib228","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.118.006242","article-title":"Circulating MicroRNA-21 Correlates With Left Atrial Low-Voltage Areas and Is Associated With Procedure Outcome in Patients Undergoing Atrial Fibrillation Ablation","volume":"11","author":"Zhou","year":"2018","journal-title":"Circ. Arrhythm. Electro"},{"issue":"5","key":"10.1016\/j.phrs.2024.107083_bib229","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jcmgh.2021.07.011","article-title":"Protective Role of microRNA-31 in Acetaminophen-Induced Liver Injury: A Negative Regulator of c-Jun N-Terminal Kinase (JNK) Signaling Pathway","volume":"12","author":"Zheng","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107083_bib230","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:49:12Z","timestamp":1760914152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":230,"alternative-id":["S1043661824000276"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107083","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107083"}}